Fallopian tube cancer
Drug research and approvals for fallopian tube cancer: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 122 studies of fallopian tube cancer are recruiting on ClinicalTrials.gov, Health Canada has authorized 35 drug trials for it since 2013, and FDA has 3 approved and 4 open orphan designations naming it.
- Recruiting worldwide: 122
- Trials authorized in Canada: 35
- FDA orphan approvals: 3
- EU medicines: 0
- Real-World Study of Mirvetuximab Soravtansine in Adult Participants With Platinum-Resistant FRα-Positive Ovarian,…NCT07896421 · Not reported · AbbVie · starts Oct 21, 2026
- Radiotherapy for Gynecologic Cancer With Up to 10 Active Metastatic LesionsNCT07883798 · Not reported · Affidea Nu-med Center of Oncological DIagnostics and Therapy · starts Oct 6, 2026
- Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Non-Homologous Recombination Deficiency (Non-HRD)…NCT07851025 · Phase 3 · AstraZeneca · starts Sep 16, 2026
- Torvutatug Samrotecan With or Without Bevacizumab as Maintenance Treatment of Platinum-sensitive Relapsed Epithelial…NCT07816666 · Phase 3 · AstraZeneca · starts Sep 24, 2026
- A Study of Raludotatug Deruxtecan With or Without Bevacizumab as First-Line Maintenance Treatment in Non-HRD-Positive…NCT07776691 · Phase 3 · Merck Sharp & Dohme LLC · starts Sep 18, 2026
- Uterine Lavage to Detect Ovarian Cancer RiskNCT07772869 · Not applicable · University of Washington · starts Sep 3, 2026
- Molecular Ovarian Cancer Assessment in LatiNoAmerican PAtientsNCT07771400 · Not reported · Latin American Cooperative Oncology Group · starts Sep 8, 2026
- A Clinical Trial of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab in Participants With Ovarian Cancer Who…NCT07743164 · Phase 3 · Merck Sharp & Dohme LLC · starts Oct 7, 2026
- A Study of SYS6043 in Platinum-Resistant, Advanced Ovarian, Primary Peritoneal, or Fallopian Tube CancersNCT07708753 · Phase 3 · CSPC Megalith Biopharmaceutical Co.,Ltd. · starts Jul 15, 2026
Approved 3
- BevacizumabVascular endothelial growth factor A inhibitor
- NiraparibPoly [ADP-ribose] polymerase 2 inhibitor
- Mirvetuximab soravtansineFolate receptor alpha binding agent
Phase 3 12 of 20
- CarboplatinDNA inhibitor
- PaclitaxelTubulin inhibitor
- TopotecanDNA topoisomerase I inhibitor
- DocetaxelTubulin inhibitor
- CyclophosphamideDNA inhibitor
- CisplatinDNA inhibitor
- GemcitabineRibonucleoside-diphosphate reductase RR1 inhibitor
- DoxorubicinDNA topoisomerase II alpha inhibitor
- RucaparibPARP 1, 2 and 3 inhibitor
- ErlotinibEpidermal growth factor receptor erbB1 inhibitor
- TrebananibAngiopoietin-1 inhibitor
- TamoxifenEstrogen receptor alpha modulator
Phase 2 12 of 80
- FilgrastimGranulocyte colony stimulating factor receptor agonist
- PembrolizumabProgrammed cell death protein 1 inhibitor
- AldesleukinInterleukin-2 receptor agonist
- SargramostimGranulocyte-macrophage colony-stimulating factor receptor agonist
- OlaparibPARP 1, 2 and 3 inhibitor
- OxaliplatinDNA inhibitor
- PazopanibMacrophage colony stimulating factor receptor inhibitor
- VeliparibPARP 1, 2 and 3 inhibitor
- NY-ESO-1
- CapecitabineThymidylate synthase inhibitor
- MetforminMitochondrial complex I (NADH dehydrogenase) inhibitor
- GefitinibEpidermal growth factor receptor erbB1 inhibitor
Phase 1 or earlier 12 of 52
- Maveropepimut-s
- IpilimumabCytotoxic T-lymphocyte protein 4 inhibitor
- Bortezomib26S proteasome inhibitor
- NivolumabProgrammed cell death protein 1 inhibitor
- EpacadostatIndoleamine 2,3-dioxygenase inhibitor
- SS1(DSFV)-PE38Mesothelin binding agent
- Incomplete freund's adjuvant
- AlemtuzumabCAMPATH-1 antigen inhibitor
- CabozantinibVascular endothelial growth factor receptor 2 inhibitor
- Etoposide phosphateDNA topoisomerase II alpha inhibitor
- EverolimusFK506-binding protein 1A inhibitor
- FloxuridineThymidylate synthase inhibitor
How its trials ended
640 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 185 whose ending is known, 28% met their primary endpoint, 15% missed it and 57% stopped early.
- Completed, result not reported23737%
- Ongoing16426%
- Status unknown548%
- Met its primary endpoint518%
- Stopped: other or unclear477%
- Missed its primary endpoint284%
- Stopped: enrollment or feasibility284%
- Stopped: sponsor or business decision132%
- Stopped: funding91%
- Stopped: lack of efficacy61%
- Stopped: safety3<1%
| Sep 23, 2026 | A phase 3, open-label, multicenter, randomized study of raludotatug deruxtecan (MK-5909, r-dxd) with or without bevacizumab versus standard-of-care…Raludotatug deruxtecan (MK-5909) / Avastin (bevacizumab) / Mvasi (bevacizumab) | Merck & Co. (MSD) | Pending |
| Aug 26, 2026 | A randomised, open-label, phase III study of torvutatug samrotecan with or without bevacizumab versus standard of care as second- or third-line maintenance…AZD5335 / Avastin / Vegzelma | AstraZeneca Pharmaceuticals | Pending |
| Aug 20, 2026 | A randomised, open-label, phase III study of torvutatug samrotecan in combination with bevacizumab versus bevacizumab monotherapy as first-line maintenance…Torvutatug samrotecan (AZD5335) / Avastin (bevacizumab) / Vegzelma (bevacizumab) | AstraZeneca Pharmaceuticals | Pending |
| Feb 26, 2026 | A randomized, open-label phase 3 study of azenosertib versus investigator’s choice of chemotherapy in platinum resistant high-grade serous ovarian, primary…Azenosertib | K-Group Beta, Inc. | Pending |
| Dec 23, 2025 | A phase 1b/2 open-label, multicenter study to evaluate the safety and efficacy of raludotatug deruxtecan with or without other anticancer investigational…MK-5909 (raludotatug deruxtecan (r-dxd)) / Keytruda / Bevacizumab / Paclitaxel… | Merck & Co. (MSD) | Ongoing |
| Jun 12, 2024 | A phase 1, first-in-human, open-label, dose-escalation and expansion study of IMGN151 (anti-fr antibody-drug conjugate) in adult patients with recurrent…IMGN151 | AbbVie | Ongoing |
| Jan 18, 2023 | A phase 3 study of relacorilant in combination with nab-paclitaxel versus nab-paclitaxel monotherapy in advanced, platinum-resistant high-grade epithelial…Relacorilant (CORT125134) / Paclitaxel | Corcept Therapeutics | Ongoing |
| Nov 9, 2022 | Randomized, multicenter, open-label, phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy…Mirvetuximab soravtansine | AbbVie | Ongoing |
| Sep 29, 2022 | Multicenter, open-label, phase 2 study of carboplatin plus mirvetuximab soravtansine followed by mirvetuximab soravtansine continuation in folate…Mirvetuximab soravtansine (IMGN853) | AbbVie | Ongoing |
| Feb 11, 2022 | Piccolo: a phase 2, single arm study of mirvetuximab soravtansine in recurrent platinum-sensitive, high-grade epithelial ovarian, primary peritoneal, or…Mirvetuximab soravtansine (IMGN853) | AbbVie | Closed |
| May 8, 2020 | LynparzaLynparza is indicated in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian,… | AstraZeneca Pharmaceuticals LP | Approved |
| Dec 19, 2018 | LynparzaLynparza® is indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic… | AstraZeneca Pharmaceuticals LP | Approved |
| Aug 17, 2017 | LynparzaMaintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in a… | AstraZeneca Pharmaceuticals LP | Approved |
| Mar 2, 2026 | RezatapoptTreatment of TP53 Y220C positive ovarian cancer, fallopian tube cancer, and primary peritoneal cancer | PMV Pharmaceuticals, Inc. | Designated |
| Aug 27, 2024 | N-[5-(2,3-Dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-fluor…Treatment of AT-rich interactive domain-containing protein 1a (ARID1a)-deficient ovarian cancer, fallopian tube cancer, and primary… | Nuvectis Pharma, Inc. | Designated |
| Feb 24, 2015 | PelareorepTreatment of fallopian tube cancer | Oncolytics Biotech, Inc. | Designated |
| Feb 2, 2010 | PatupiloneTreatment of primary fallopian tube cancer. | Novartis Pharmaceuticals Corporation | Designated |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA